北京市东城 区北三环东 路36号环球 贸易中心 B 座 11 层 电话（Tel）： 52213236/7 邮编（P.C）： 100013 北京市君致律师事务所 关于山东新华医疗器械股份有限公司 北京市君致律师事务所（以下简称"本所"）受山东新华医疗器械股份有限公 司（以下简称"公司"）的委托，指派律师出席 2024 年 4 月 18 日上午 9:00 点召 开的公司 2023 年度股东大会（以下简称"本次股东大会"）；依据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上市公司股东大会规则》（以下简称"《股东大会规则》"）等现行法 律、法规和其他规范性文件及《山东新华医疗器械股份有限公司章程》的规定， 特就公司本次股东大会相关事宜，出具本法律意见书。 致：山东新华医疗器械股份有限公司 2023 年度股东大会的法律意见书 对本法律意见书的出具，本所特作如下声明： 1、本所及经办律师依据《证券法》、《律师事务所从事证券法律业务管理办 法》和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前 已经发生或者存在的事实，严格履行了法定职责，遵循 ...

Investment Rating - The report maintains an "Outperform" rating for the company [1] Core Views - The company's main business gross margin has improved, with a focus on medical devices and pharmaceutical equipment manufacturing, which accounted for 61.5% of the main business revenue in 2023, up 2.5 percentage points year-on-year [4] - The company's international business achieved a breakthrough, with revenue reaching 241 million yuan in 2023, a 55.36% increase year-on-year, and the gross margin of international business is significantly higher than that of domestic business [4] - The company continues to divest inefficient and non-performing assets, further focusing its business [4] - The pharmaceutical equipment segment achieved revenue of 1.923 billion yuan in 2023, a 26.73% year-on-year increase, with significant growth in international contracts [5] - The medical devices segment achieved revenue of 4.167 billion yuan in 2023, a 9.15% year-on-year increase, with key progress in national-level R&D projects and breakthroughs in the biosafety market [17] Financial Performance - The company achieved revenue of 10.012 billion yuan in 2023, a 7.87% year-on-year increase, with net profit attributable to the parent company of 654 million yuan, a 30.78% year-on-year increase [16] - The gross margin in 2023 was 27.37%, up 0.93 percentage points year-on-year [4] - The company's net profit is expected to grow by 25.0%, 19.4%, and 15.1% year-on-year from 2024 to 2026, reaching 818 million yuan, 976 million yuan, and 1.124 billion yuan, respectively [18] - The company's revenue is expected to grow by 8.1%, 7.7%, and 7.7% year-on-year from 2024 to 2026, reaching 10.821 billion yuan, 11.655 billion yuan, and 12.549 billion yuan, respectively [19] Market Performance - The company's stock price has shown significant fluctuations, with a 52-week range of 17.12 to 36.95 yuan [14] - The company's total market capitalization is 10.734 billion yuan, with a circulating market capitalization of 10.238 billion yuan [14] Industry and Competitive Landscape - The company is expected to benefit from the new infrastructure in the pharmaceutical industry and the incremental demand in the pharmaceutical equipment sector, with rapid development in both medical devices and pharmaceutical equipment segments [18] - The company's product upgrades and structural optimization are expected to further enhance profitability [18] Financial Projections - The company's EPS is expected to be 1.75 yuan, 2.09 yuan, and 2.41 yuan in 2024, 2025, and 2026, respectively [19] - The company's gross margin is expected to be 27.6%, 28.1%, and 28.7% in 2024, 2025, and 2026, respectively [19] - The company's ROE is expected to be 10.1%, 10.9%, and 11.3% in 2024, 2025, and 2026, respectively [19]

山东新华医疗器械股份有限公司 2023 年年度股东大会资料 二О二四年三月二十七日 新华医疗 2023 年年度股东大会 山东新华医疗器械股份有限公司 2023 年年度股东大会会议议程 现场会议时间：2024 年 4 月 18 日（周四）上午 9:00 现场会议地点：公司办公楼三楼会议室 现场会议地址：山东省淄博市高新技术产业开发区泰美路 7 号新华医疗科技园 现场会议议程： 1、选举监票人 ； 2、审议《2023 年年度报告全文及摘要》； 3、审议《2023 年度董事会工作报告》； 4、审议《2023 年度监事会工作报告》； 5、审议《2023 年度财务决算报告及 2024 年度财务预算报告》； 6、审议《2023 年度利润分配预案》； 7、审议《2023 年度独立董事述职报告》； 8、审议《关于续聘天职国际会计师事务所（特殊普通合伙）为公司 2024 年度财 务审计机构和内部控制审计机构的议案》； 9、审议《关于对外担保的议案》； 10、审议《关于向银行申请综合授信额度并予以相应授权的议案》； 11、审议《关于修订<独立董事工作制度>的议案》； 12、审议《公司未来三年分红回报规划(2024-2026 年) ...

证券代码：600587 证券简称：新华医疗 公告编号：临 2024-014 山东新华医疗器械股份有限公司 关于召开 2023 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 4 月 12 日(星期五) 至 4 月 18 日(星期四)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 shinva@163.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 山东新华医疗器械股份有限公司（以下简称"公司"）已于 2024 年 3 月 29 日发布公司 2023 年年度报告，为便于广大投资者更全面深入地了解公司 2023 年度经营成果、财务状况，公司计划于 2024 年 4 月 19 日上午 09:00-10:00 举行 2023 年度业绩暨现金分红说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以 ...

请务必阅读正文后的重要声明部分 [Table_Summary 事件：公司发布] 2023 年年报，2023 年实现营业总收入 100.1 亿元，同比增加 7.9%；归母净利润 6.5 亿元，同比增加 30.8%；扣非归母净利润 6.2 亿元，同 比增加 23.2%。 加大研发投入，国际市场发展迅速。2023年公司研发费用 4.43亿，持续加大研 发投入力度，公司 2023年度申请专利 419项，其中发明专利 87项，入选国家 知识产权优势企业，连续三年入选中国企业专利实力 500 强。同时公司坚持国 内国际"双循环"。2023 年公司实现国际业务收入（自营）24132 万元，比上 年同期增长 55.36%，国际业务毛利率达到 50.94%，伴随着公司产品质量不断 提高，国际订单的稳步增长，公司未来国际市场收入增长可期。 | --- | --- | --- | --- | --- | |----------------------------|--------|-------------------------------------|--------|--------| | | | | | | | 营业收入（ ...

证 券 研 究 报 告 产品结构持续改善，国际业务高速增长 目标价：32 元 当前价：22.86 元 公司发布 2023 年年报，营收为 100.12 亿元（+7.87%），归母净利润为 6.54 亿 元（+30.78%），扣非净利润为 6.19 亿元（+23.20%）。Q4 单季度营收为 26.95 亿元（+2.42%），归母净利润为 0.75 亿元（-5.99%），扣非净利润为 0.64 亿元 （-9.74%）。 评论： | --- | --- | --- | --- | --- | |---------------------|--------|--------|--------|--------| | | 2023A | 2024E | 2025E | 2026E | | 营业总收入 ( 百万 ) | 10,012 | 11,143 | 12,315 | 13,562 | | 同比增速 (%) | 7.9% | 11.3% | 10.5% | 10.1% | | 归母净利润 ( 百万 ) | 654 | 833 | 1,038 | 1,282 | | 同比增速 (%) | 30.1% | 27.3% ...

公司研究 ——新华医疗（600587.SH）2023 年业绩点评 事件：公司发布 2023 年业绩，全年营业收入 100.12 亿元，同比增长 7.87%， 归母净利润 6.54 亿元，同比增长 30.78%，扣非归母净利润 6.19 亿元，同比增 长 23.20%；业绩符合市场预期。 收入结构持续优化，计提减值影响 23Q4 利润。公司 2023 年实现营业收入 100.12 亿元（YOY+7.87%），归母净利润 6.54 亿元（YOY+30.78%），扣非归母净利 润 6.19 亿元（YOY+23.20%），其中 23 年单 Q4 实现营业收入 26.95 亿元 （YOY+2.42%），归母净利润 0.75 亿元（YOY-5.99%），扣非归母净利润 0.64 亿元（YOY-9.74%）。23Q4 归母净利润同比下降主要是当季公司计提 0.33 亿 元资产减值损失和 0.75 亿元信用减值损失。23 年销售费用率 9.12%，同比下降 0.45pct，管理费用率 5.20%，同比提升 0.23pct，研发费用率 4.43%，同比提 升 0.11pct。截至 2023 年末，公司持有合同负债 23.36 ...

Investment Rating - The report maintains a "Buy" rating for the company [11][22]. Core Views - The company's revenue growth in 2023 met expectations, with total revenue reaching 10.01 billion yuan, a year-on-year increase of 7.87%. The net profit attributable to shareholders was 654 million yuan, up 30.78% year-on-year [1][11]. - The decline in profit in Q4 2023 was attributed to asset impairment losses, which amounted to 32.54 million yuan, and credit impairment losses of 74.61 million yuan. Excluding these losses, the adjusted net profit for Q4 was 182 million yuan, reflecting a year-on-year growth of 30.32% [1][11]. - The company is experiencing a shift in revenue structure, with a higher proportion of high-margin manufacturing products. Revenue from medical device products reached 4.15 billion yuan, a year-on-year increase of 9.15% [1][11]. - The international business is showing significant growth, with self-operated international revenue reaching 241 million yuan, a year-on-year increase of 55.36%, and an international gross margin of 50.94% [1][11]. Financial Performance Summary - In 2023, the company achieved total revenue of 10.01 billion yuan, with a projected revenue growth of 10.8% in 2024, 10.7% in 2025, and 10.2% in 2026 [3][11]. - The net profit attributable to shareholders is expected to grow to 817 million yuan in 2024, 1.009 billion yuan in 2025, and 1.232 billion yuan in 2026, with respective growth rates of 24.9%, 23.5%, and 22.1% [3][11]. - The company's earnings per share (EPS) for 2023 was 1.40 yuan, with projections of 1.75 yuan in 2024, 2.16 yuan in 2025, and 2.64 yuan in 2026 [3][11]. Dividend Policy - The company plans to distribute a cash dividend of 5 yuan for every 10 shares, totaling 233 million yuan, resulting in a dividend payout ratio of 35.68% [1][11].

中信建投证券股份有限公司（以下简称"保荐机构"）作为山东新华医疗器 械股份有限公司（简称"上市公司"、"公司"或"新华医疗"）非公开发行 A 股 股票项目的保荐机构，根据《证券发行上市保荐业务管理办法》（以下简称"《保 荐办法》"）以及《上海证券交易所上市公司自律监管指引第 11 号——持续督导》 （以下简称"《持续督导工作指引》"）等相关法规规定，担任本次非公开发行股 票项目持续督导的保荐机构，于 2024 年 3 月 26 日对公司进行了现场检查。现将 本次现场检查情况报告如下： 一、本次现场检查的基本情况 保荐机构于 2024 年 3 月 26 日对上市公司进行了现场检查。参加人员为保荐 代表人田斌。 在现场检查过程中，保荐机构结合上市公司的实际情况，查阅、收集了上市 公司有关文件、资料，与公司相关人员进行了访谈，实施了包括审核、查证、询 问等必要程序，检查了公司治理和内部控制，信息披露，公司的独立性以及与控 股股东及其他关联方资金往来，募集资金使用，关联交易、对外担保、重大对外 投资以及经营状况等情况，并在前述工作的基础上完成了本次现场检查报告。 中信建投证券股份有限公司关于山东新华医疗器械股份有 限 ...

Financial Performance - The company's operating revenue for 2023 reached RMB 10,011,868,423.40, an increase of 7.87% compared to RMB 9,281,768,657.18 in 2022[23] - The net profit attributable to shareholders of the listed company was RMB 653,997,275.95, reflecting a growth of 30.78% from RMB 500,072,195.90 in the previous year[23] - The net cash flow from operating activities significantly increased by 165.46% to RMB 1,030,114,479.17, compared to RMB 388,048,566.87 in 2022[23] - The total assets of the company at the end of 2023 amounted to RMB 15,590,329,775.23, a 20.29% increase from RMB 12,960,969,829.16 in 2022[23] - The net assets attributable to shareholders of the listed company increased by 35.76% to RMB 7,318,625,200.44, compared to RMB 5,390,937,164.40 at the end of 2022[23] - Basic earnings per share for 2023 were RMB 1.43, up 16.26% from RMB 1.23 in 2022[24] - The total net profit attributable to shareholders was CNY 653.99 million, representing a growth of 30.78% year-on-year[32] - In 2023, the net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 619.45 million, an increase of 23.20% compared to the previous year[32] Revenue Breakdown - Revenue from manufacturing products, including medical devices and pharmaceutical equipment, accounted for 61.49% of total operating income, up 16.84 percentage points from 44.65% in 2020[35] - International business revenue reached CNY 241.32 million, a year-on-year increase of 55.36%, with a gross margin of 50.94%[36] - Revenue from medical device manufacturing was CNY 4.17 billion, a 9.15% increase year-on-year[37] - Revenue from pharmaceutical equipment was CNY 1.92 billion, showing a growth of 26.73% compared to the previous year[37] - Revenue from medical services reached CNY 921.75 million, increasing by 9.42% year-on-year[37] - Revenue from medical trading products was CNY 2.89 billion, a slight decrease of 0.07% compared to the previous year[37] Research and Development - Research and development expenses amounted to CNY 443.37 million, reflecting a 10.49% increase from the previous year[36] - The company achieved a significant increase in R&D investment intensity, surpassing the industry average and narrowing the gap with leading medical device companies[38] - The company has established a three-tier product R&D system, focusing on market-oriented innovation and rapid product upgrades[57] - The company plans to continue increasing R&D investment and deepen structural reforms during the "14th Five-Year Plan" period[60] - Total R&D investment was 443.37 million yuan, representing 4.43% of operating revenue[79] Market Expansion and Strategy - The company is committed to ongoing research and development of new products and technologies to enhance market expansion and competitiveness[6] - The company has established four regional sales centers to enhance market penetration among high-end products and major hospitals[39] - Xinhua Medical's revenue from exports is rapidly growing, with successful projects in Pakistan and Indonesia approved during the Belt and Road Entrepreneurs Conference[39] - The company is actively pursuing talent acquisition, having successfully introduced national-level talents and established a postdoctoral research station[42] - The company is exploring market expansion opportunities, particularly in the medical device sterilization segment, to capture a larger market share[94] Corporate Governance and Compliance - The company has established a modern corporate governance structure in compliance with relevant laws and regulations, ensuring the protection of shareholders' rights[123] - The board of directors includes four independent directors, constituting one-third of the board, ensuring compliance and risk management[124] - The company emphasizes the importance of maintaining the rights of stakeholders, including creditors and employees, to promote healthy development[125] - The company has implemented internal control measures in line with the Basic Norms for Internal Control issued by five ministries[125] - The company has committed to not engaging in substantial competition with its own subsidiaries in the specialized medical services sector[127] Environmental Responsibility - The company invested 4.2527 million RMB in environmental protection during the reporting period[174] - Xinhua Medical was listed as a key pollutant discharge unit in Zibo City for 2023, with COD emissions of 6.166 tons and ammonia nitrogen emissions of 3.709 tons, both of which were within the standard limits[176] - The company has implemented a comprehensive environmental management system in accordance with GB/T24001-2016 standards to ensure compliance with environmental regulations[185] - The company has established an emergency response plan for environmental incidents, valid until June 6, 2025, and has conducted regular drills[179] - The company has conducted environmental monitoring, including quarterly checks of wastewater and air emissions, ensuring compliance with discharge permits[180] Future Outlook - The company has outlined a future outlook with a projected revenue growth of 10% for the next fiscal year[95] - The company aims to improve operational efficiency, targeting a 5% reduction in production costs by 2025[95] - The company plans to enhance its market presence through the introduction of innovative sterilization methods and packaging technologies, which are expected to improve product safety and shelf life[96] - The company is committed to advancing its technology in medical equipment, with several patents filed for new sterilization devices and automated production lines[96] - The company has set ambitious performance guidance for the upcoming fiscal year, projecting a revenue growth rate of approximately 15%[96] Legal and Regulatory Matters - The company is currently involved in a patent infringement lawsuit initiated by 3M, seeking a total compensation of RMB 80 million, which was later increased to RMB 60 million[200] - As of July 2023, the company has recognized a provision of RMB 19.85 million related to the lawsuit and included it in operating expenses[200] - The company has initiated a nullification procedure against the patent in question, with a court hearing scheduled for February 26, 2024[200] - The company has filed a request with the National Intellectual Property Administration for a declaration of invalidity concerning the patent involved in the lawsuit[200] - The company has not faced any delisting risk or bankruptcy reorganization issues during the reporting period[197]